From: Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
CRUDE | ADJUST | ||||||
---|---|---|---|---|---|---|---|
Variable | OR | 95 % CI | p-value | OR | 95 % CI | p-value | |
Age | |||||||
17–44(reference) | |||||||
45–64 | 1.2027 | 0.95–1.52 | 0.1260 | 1.3581 | 1.02–1.81 | 0.0384 | |
>=65 | 0.3282 | 0.25–0.43 | < 0.0001 | 0.4068 | 0.28–0.60 | < 0.0001 | |
Female sex | 0.9229 | 0.79–1.08 | 0.3190 | 1.0209 | 0.83–1.26 | 0.8491 | |
BMI, kg/m2 | 1.2654 | 1.21–1.33 | < 0.0001 | 1.2723 | 1.20–1.35 | < 0.0001 | |
DM duration (per year) | 0.9564 | 0.94–0.98 | < 0.0001 | 0.9806 | 0.92–1.04 | 0.5203 | |
DM duration, yr | |||||||
< 5 (reference) | |||||||
5 ~ 9 | 1.3008 | 0.99–1.71 | 0.0601 | 1.1535 | 0.78–1.71 | 0.4759 | |
10 ~ 14 | 0.8289 | 0.64–1.08 | 0.1637 | 0.9427 | 0.67–1.33 | 0.7388 | |
> 15 | 0.6581 | 0.51–0.84 | 0.0009 | 0.9195 | 0.47–1.82 | 0.8090 | |
HbA1c | 1.5200 | 1.34–1.72 | < 0.0001 | 1.4504 | 1.24–1.70 | < 0.0001 | |
Albuminuria categories | |||||||
A2(reference) | |||||||
A3 | 0.9796 | 0.84–1.15 | 0.8000 | 0.9213 | 0.75–1.14 | 0.4460 | |
Diabetic retinopathy | 1.2183 | 1.04–1.42 | 0.0122 | 1.4757 | 1.18–1.84 | 0.0005 | |
Cancer | 0.5636 | 0.38–0.83 | 0.0033 | 0.6862 | 0.43–1.11 | 0.1224 | |
Recent hospitalization | 0.6951 | 0.55–0.87 | 0.0017 | 0.6007 | 0.44–0.82 | 0.0011 | |
CVD-HF | 1.0782 | 0.92–1.26 | 0.3380 | 0.7312 | 0.41–1.32 | 0.2980 | |
Heart failure | 2.6806 | 1.62–4.44 | < 0.0001 | 5.1875 | 2.56–10.49 | < 0.0001 | |
Stroke | 0.6422 | 0.49–0.85 | < 0.0001 | 0.9431 | 0.57–1.57 | 0.8221 | |
CAD | 1.2914 | 1.09–1.53 | < 0.0001 | 1.9390 | 1.10–3.40 | 0.0211 | |
PAOD | 0.7000 | 0.40–1.22 | 0.2063 | 1.0210 | 0.48–2.18 | 0.9572 |